Investigational drug study for Acute Myeloid Leukemia (AML)

Trial ID:
IRB-17-7018
James Mason, M.D.
This study will evaluate the safety and effectiveness of investigational drug, Pracinostat, in combination with Azacitadine for people who are newly diagnosed with AML and are unfit to receive intensive chemotherapy regimen due to advanced age or other medical conditions.

Inclusion Criteria

  • Be newly diagnosed with Acute Myeloid Leukemia (AML) and have not been previously treated
  • Be unable to tolerate an intensive chemotherapy regimen due to age or another medical condition.
  • Be willing and able to undergo bone marrow aspiration and biopsy at the start of and during the study.

Exclusion Criteria

  • Have had other cancers within 12 months (certain breast, cervical, skin or prostate are allowed)
  • Have received prior treatment with histone deacetylase (HDAC) inhibitors
  • Have gastrointestinal tract disease that causes an inability to take oral medication.
  • Be pregnant or planning to become pregnant.

Additional Info

  • Pracinostat inhibits specific proteins that may stop or reverse the growth of cancerous cells. Azacitidine is approved by the FDA for the treatment of AML. Both drugs will be given together.
  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.

Contact Info: